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Abstract
AIM: To evaluate the diagnostic and prognostic value 
of circulating Metastasis Associated in Colon Cancer 1 
(MACC1) transcripts in plasma of gastric cancer patients.
METHODS: We provide for the first time a blood-based 
assay for transcript quantification of the metastasis 
inducer MACC1 in a prospective study of gastric cancer 
patient plasma. MACC1 is a strong prognostic biomarker 
for tumor progression and metastasis in a variety of 
solid cancers. We conducted a study to define the 
diagnostic and prognostic power of MACC1 transcripts 
using 76 plasma samples from gastric cancer patients, 
either newly diagnosed with gastric cancer, newly 
diagnosed with metachronous metastasis of gastric 
cancer, as well as follow-up patients. Findings were 
controlled by using plasma samples from 54 tumor-free 
volunteers. Plasma was separated, RNA was isolated, 
and levels of MACC1 as well as S100A4 transcripts were 
determined by quantitative RT-PCR.
RESULTS: Based on the levels of circulating MACC1 
transcripts in plasma we significantly discriminated tumor-
free volunteers and gastric cancer patients (P < 0.001). 
Levels of circulating MACC1 transcripts were increased in 
gastric cancer patients of each disease stage, compared 
to tumor-free volunteers: patients with tumors without 
metastasis (P = 0.005), with synchronous metastasis (P 
= 0.002), with metachronous metastasis (P = 0.005), 
and patients during follow-up (P = 0.021). Sensitivity was 
0.68 (95%CI: 0.45-0.85) and specificity was 0.89 (95%CI: 
0.77-0.95), respectively. Importantly, gastric cancer 
patients with high circulating MACC1 transcript levels in 
plasma demonstrated significantly shorter survival when 
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transcripts in gastric cancer patient plasma as diagnostic 
and prognostic biomarker
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compared with patients demonstrating low MACC1 levels 
(P = 0.0015). Furthermore, gastric cancer patients with 
high circulating transcript levels of MACC1 as well as of 
S100A4 in plasma demonstrated significantly shorter 
survival when compared with patients demonstrating 
low levels of both biomarkers or with only one biomarker 
elevated (P = 0.001).
CONCLUSION: Levels of circulating MACC1 transcripts 
in plasma of gastric cancer patients are of diagnostic 
value and are prognostic for patient survival in a 
prospective study.
Key words: Gastric cancer; Plasma; Circulating 
transcripts; MACC1; S100A4; Diagnosis; Prognosis; 
Survival
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Core tip: We provide for the first time a blood-based 
assay for transcript quantification of the metastasis 
inducer Metastasis Associated in Colon Cancer 1 (MACC1) 
in a prospective study of gastric cancer patients. 
MACC1 is a strong prognostic biomarker for tumor 
progression and metastasis in a variety of solid cancers. 
We discriminated tumor-free volunteers and gastric 
cancer patients (all P  < 0.001, sensitivity 0.68 (95%CI: 
0.45-0.85), specificity 0.89 (95%CI: 0.77-0.95) of each 
disease stage (P  < 0.05 for each). Shorter survival 
correlated with high circulating MACC1 transcript levels (P  
= 0.0015). Thus, circulating MACC1 transcript levels in 
plasma of gastric cancer patients are of diagnostic value 
and are prognostic for patient survival.
Burock S, Herrmann P, Wendler I, Niederstrasser M, Wernecke 
KD, Stein U. Circulating metastasis associated in colon cancer 
1 transcripts in gastric cancer patient plasma as diagnostic 
and prognostic biomarker. World J Gastroenterol 2015; 
21(1): 333­341  Available from: URL: http://www.wjgnet.
com/1007­9327/full/v21/i1/333.htm  DOI: http://dx.doi.
org/10.3748/wjg.v21.i1.333
INTRODUCTION
Gastric cancer is one of  the major malignancies in the 
world with an estimated incidence of  140 cases per 100000 
people in Europe in 2012[1]. Although there is a steady 
decline in gastric cancer mortality it is still the fourth 
most common cause of  death from cancer as it is mainly 
diagnosed at an advanced stage. Overall survival is 
clearly linked to disease stage and metastasis formation. 
Despite the recent developments in both, chemotherapy 
and surgical treatment, the outcome for patients with 
distant metastasis is still poor with a 5-year survival rate 
of  less than 5% compared to 60% for patients with only 
localised malignancies[2]. Therefore, detecting the disease 
already at an early stage and identifying that patient 
cohort with a high risk of  developing metastasis is crucial 
and could lead to a significant better outcome.
In previous studies we have identified the previously 
undescribed gene Metastasis-Associated in Colon Cancer 
(MACC1)[3]. MACC1 induces cell proliferation, cell motility 
such as migration and invasion, as well as dissemination in 
cell culture. MACC1 regulates the transcription of  genes 
important for the development of  metastasis, such as 
the receptor tyrosine kinase Met. Furthermore, MACC1 
induces metastasis formation in several xenografted 
mouse models. Following our initial publication, a variety 
of  groups provided evidence that MACC1 contributes 
to fundamental biological processes such as apoptosis 
and Epithelial-Mesenchymal Transistion via well-known 
pathways such as the Hepatocyte Growth Factor (HGF)/
met protooncogen (Met)/MACC1 axis. Thus, MACC1 
was confirmed as decisive driver for tumorigenesis and 
metastasis[4].
MACC1 is an independent prognostic indicator 
for colon cancer metastasis formation and allows iden-
tification of  high-risk subjects in early stages[3,5,6]. The role 
of  MACC1 as prognostic biomarker for colorectal cancer 
patients with respect to time of  progression, metastasis 
formation, and overall survival was meanwhile confirmed 
in a panel of  independent studies using different 
techniques for MACC1 detection in tissues and blood[4]. 
Furthermore, the importance of  MACC1 was extended by 
cross-entity approaches to a variety of  several other solid 
cancers such as pancreatic, hepatocellular, hepatobiliary, 
lung, ovarian, breast, nasopharyngeal, esophageal, 
kidney, bladder, gallbladder cancers, to glioblastomas and 
osteosarcomas[4].
In gastric primary tumors, the presence of  MACC1 
correlated with peritoneal metastasis, lymph node 
metastasis and hepatic metastasis, and finally to a poor 
prognosis for the patients[7]. Wang and colleagues 
described an association of  high MACC1 expression in 
the primary tumors of  gastric cancer patients with more 
advanced disease, more frequent postoperative recurrence, 
more metastases, higher mortality rate, and worse 
survival[8]. Furthermore, a high expression of  MACC1 in 
gastric tumors was found to be correlated with peritoneal 
dissemination of  the tumor[9]. All these findings underline 
the importance of  MACC1 as a biomarker for tumor 
progression, metastasis and survival also for gastric cancer 
patients.
However, molecular analyses of  tumor tissues have 
some limitations due to a restricted availability of  tumor 
tissue, intra-tumoral heterogeneity and the invasive 
character of  tumor biopsies. Therefore, the establishment 
of  blood-based tests have become more and more im-
portant. Lately we described a non-invasive, blood-
based assay for circulating MACC1 transcript levels and 
demonstrated its diagnostic and prognostic value in the 
plasma of  colorectal cancer patients; analyses were based 
on the biomarker MACC1 alone as well as in combination 
with the previously described metastasis gene S100A4 
with respect to an improved prediction of  outcome[10,11].
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Table 1  Patients’ characteristics
For gastric cancer patients, however, such a test is 
neither developed nor evaluated with respect to diagnose 
gastric cancer patients vs tumor-free volunteers or con-
cerning the prognosis of  the disease. Thus, here we aim to 
evaluate the diagnostic and prognostic value of  circulating 
MACC1 transcripts in plasma of  a patient cohort with 
gastric cancer. We hypothesize that analysing the MACC1 
levels in liquid biopsies of  gastric cancer patients might 
also be of  benefit for patients as demonstrated for patients 
suffering from other gastrointestinal cancers such as colon 
and rectal cancer, also developing distant metastases[10]. 
Furthermore, we will combine this MACC1 data with 
those of  circulating transcripts of  the metastasis gene 
S100 calcium binding protein A4 (S100A4) for potential 
improvement of  disease prognosis.
MATERIALS AND METHODS
Patient data and classification
We analyzed 76 blood samples of  consecutive gastric 
cancer patients who were treated at the Robert Rössle 
Cancer Hospital, Charité University Medicine Berlin, 
during March 2006 until March 2007 for the first or for 
a further time. Patients’ data for survival and the routine 
histopathological characterization of  the tumor (including 
tumor infiltration, lymph node status, metastasis, grading, 
lymphatic vessels infiltration, blood vessels infiltration, 
residual tumor) were available from the tumor bank. 
Exclusion criteria were tumor development of  another 
entity during history or follow-up. For more details of  the 
patients’ characteristics see Table 1.
Blood samples of  patients with newly diagnosed 
gastric cancer and blood samples of  patients with newly 
diagnosed metachronous metastasis of  gastric cancer 
were taken at the day of  diagnosis. Blood samples from 
the cohort of  follow-up patients were taken exclusively 
during the follow-up (median 1003 d after primary 
diagnosis) with a median follow-up period of  852 d after 
blood taking. Six blood samples out of  54 were from 
patients who developed metastasis later on (median 270 
d after blood taking).
The plasma controls derived from two independent 
cohorts of  healthy volunteers (n = 54). Median age 
of  the tumor-free volunteers at the time of  blood 
taking was 61 (27-87). The cohort of  the tumor-free 
volunteers consisted of  43 male and 11 female tumor-
free volunteers. Recruitment of  the volunteers was 
supported by Klaus Sperber, Medical Practioner, Berlin, 
and by Ursula Plöckinger, Charité Campus Virchow 
Klinikum, Berlin. All volunteers were tumor-free and 
had no history of  oncological diseases. We did not find 
significantly different MACC1 levels within the two 
cohorts of  tumor-free volunteers, nor differences with 
respect to gender or age of  the healthy individuals.
All blood specimens from patients and tumor-
free volunteers were collected after written informed 
consent in accordance with the International Conference 
on Harmonisation and with the approval of  the local 
Institutional Review Board.
Plasma preparation
Plasma separation was performed from cooled EDTA-
blood at the same day within 7 h post blood taking. 
Procedure for plasma separation from blinded samples 
was as previously described[10,11]. Samples were stored at 
-80 ℃.
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Primary diagnosis Follow-up All cancer patients
W/o synchronous 
organ metastasis
With synchronous 
organ metastasis
With metachronous 
organ metastasis
Samples, n     9     8     5 54   76
AJCC/UICC Ⅰ, %   67     0   80 48   47
T1-T2, N0, M0
T1, N1, M0
AJCC/UICC Ⅱ, %   11     0     0 28   21
T1, N2, M0
T2, N1, M0
T3, N0, M0
AJCC/UICC Ⅲ, %   11     0   20 24   20
T2, N2, M0
T3, N1, M0
T4, N0, M0
T3, N2, M0
AJCC/UICC Ⅳ, %   11 100     0   0   12
T4, N1-2, M0
Every T, N3, M0 every T, every N, M1
Median follow up, after blood taking (d) 677 351 169 851, 5 803
Age at blood taking, median (range) (yr) 63 (48-77) 59 (56-68) 71 (39-83) 63 (40-86) 63 (39-86)
Sex, m/f 8/1 7/1 4/1 38/16 57/19
P, vs tumor-free volunteers P = 0.005 P = 0.002 P = 0.005 P = 0.021 P < 0.001
UICC: Union internationale contre le cancer; AJCC: American joint committee on cancer.
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Quantitative real-time reverse transcriptase-polymerase 
chain reaction
Isolation of  total RNA and quantitative real-time 
reverse transcriptase-polymerase chain reaction (qRT-
PCR) were performed as previously described[10,11]. 
Briefly, after 30 s at 95 ℃, we run 45 cycles of  10 s 
95 ℃, 10 s 62 ℃, 10 s 72 ℃, and a melting curve from 
40 ℃ to 95 ℃, using the LightCycler (DNA Master 
Hybridization Probes kit, Roche Diagnostics). Thereby 
we amplified a 136 bp MACC1-specific PCR product 
with the following primers and probes: forward primer 5’
-TTCTTTTGATTCCTCCGGTGA-3’, reverse primer 5’
-ACTCTGATGGGCATGTGCTG-3’, FITC-probe 5’
-GCAGACTTCCTCAAGAAATTCTGGAAGATCTA-3’, 
LCRed640-probe 5’-AGTGTTTCAGAACTTCT-
GGACATTTTAGACGA-3’ (syntheses of  primers and 
probes: BioTeZ and TIB MolBiol, Berlin, Germany). 
The calibrator cDNA derived from the cell lines SW620 
(authentification of  the cell line by short tandem repeat (STR) 
genotyping, German Collection of  Microorganisms and Cell 
Cultures, Braunschweig, Germany).
S100A4-specific qRT-PCR was performed as 
previously described. MACC1 and S100A4 mRNA expre-
ssions are given as percentage of  the mRNA expression 
of  a calibrator sample, which was set 100%. Each sample 
was run and calculated in duplicate, the means are 
depicted.
Statistical analysis
We tested differences between groups in terms of  MACC1 
transcript levels in plasma by using non-parametric (exact) 
Wilcoxon- Mann-Whitney tests (because of  deviations 
of  the distributions from normality and small samples). 
Samples obtained from tumor-free volunteers were com-
pared with those from patients with primary tumors 
without and with synchronous organ metastases, patients 
with metachronous metastases, and follow-up patients. 
Furthermore, samples obtained from patients with tumors 
vs those with tumors and metastases were compared. Results 
are expressed as median (range) or frequencies (%). P < 0.05 
was considered to be significant. All tests were conducted 
in the area of  exploratory data analysis. Therefore, no 
adjustments for multiple testing have been made.
For evaluating the diagnostic value of  circulating 
MACC1 transcripts in plasma of  gastric cancer patients, 
we calculated sensitivity and specificity with a fourfold 
table for those cancer patients, who were newly diagnosed 
with a primary tumor without or with synchronous 
metastases compared to the blood samples of  54 tumor-
free volunteers.
We used Kaplan Meier curves in combination with 
log rank test for survival analyses of  newly diagnosed and 
of  all gastric patients. Both biomarkers, MACC1 as well 
as S100A4, could be determined in 70 plasma samples. 
The respective cut-off  values for the biomarkers were 
the median of  the investigated groups (primary diagnosis 
or all patients). We performed all calculations with SPSS, 
version 21.
RESULTS
Circulating MACC1 transcripts in plasma classify 
tumor-free volunteers and gastric cancer patients
First, we tested on whether the levels of  circulating MACC1 
transcripts are different in tumor-free volunteers (n = 54) 
and gastric cancer patients (n = 76). We detected MACC1 
transcripts in all samples analyzed. Significantly higher 
MACC1 levels were measured in cancer patient plasma 
(median 0.334 MACC1 mRNA expression/percent 
calibrator) compared to the tumor-free individuals (median 
0.224 MACC1 mRNA expression/percent calibrator; P < 
0.001; Figure 1). We observed no significant variations of  
MACC1 levels due to age or sex.
We then tested the levels of  MACC1 of  different disease 
stages with respect to the tumor-free volunteers, such as 
tumors without metastasis (median 0.531 MACC1 mRNA 
expression/percent calibrator; P = 0.005), with synchronous 
metastasis (median 0.655 MACC1 mRNA expression/
percent calibrator; P = 0.002), with metachronous metastasis 
(median 0.561 MACC1 mRNA expression/percent 
calibrator; P = 0.005), and during follow-up (median 0.272 
MACC1 mRNA expression/percent calibrator; P = 0.021). 
Interestingly, levels of  MACC1 were significantly higher 
in each disease stage when compared with tumor-free 
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Figure 1  Circulating metastasis associated in colon cancer 1 transcript 
levels in plasma discriminate gastric cancer patients from tumor-free 
volunteers. Levels of circulating metastasis associated in colon cancer 1 
(MACC1) transcripts in plasma of all gastric cancer patients (n = 76) were 
significantly higher than in tumor-free volunteers (n = 54; P < 0.001). All patient 
subcohorts demonstrated significantly higher levels of circulating MACC1 
transcripts when compared to the tumor-free volunteers: patients in stages Ⅰ to 
Ⅳ (M0) (P = 0.005), patients in stage Ⅳ (M1) (P = 0.002), patients with 
metachronous metastasis (P = 0.005), and patients during follow-up (P = 0.021). 
Box plot analysis based on quantitative real-time RT-PCR.
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volunteers (Figure 1).
To evaluate sensitivity and specificity of  this blood-
based assay for circulating MACC1 transcript levels, 
values were calculated with a fourfold table for patients 
with present gastric cancer. More precisely, blood samples 
of  patients with newly diagnosed primary gastric cancer 
(with or without synchronous metastases), and patients 
who already underwent R0-surgery of  primary gastric 
cancer and were newly diagnosed with metachronous 
metastases were compared to the tumor-free volunteers 
with consecutive cut-off  values. The MACC1 transcript 
level with the highest sum of  specificity and sensitivity 
was selected as the optimal cut-off  point[12]. This resulted 
in a cut-off  point of  0.504 MACC1 mRNA expression/% 
calibrator with a sensitivity of  0.68 (95%CI: 0.45-0.85) and 
a specificity of  0.89 (95%CI: 0.77-0.95). Thus, MACC1 
transcript levels in plasma support the identification 
of  individuals suffering of  gastric cancer and might 
contribute to the identification of  metastasis formation.
Circulating MACC1 transcript levels in plasma are 
prognostic for gastric cancer patient survival
To investigate the prognostic value of  high vs low MACC1 
transcript levels in the plasma of  gastric cancer patients 
within this prospective study, survival analysis were 
performed with Kaplan Meier curves in combination with 
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Figure 2  Overall survivals of gastric cancer patients. A: Overall survival of gastric cancer patients based on circulating transcript levels of metastasis associated in 
colon cancer 1.  Gastric cancer patients with high circulating metastasis associated in colon cancer 1 (MACC1) transcript levels in plasma demonstrated significantly 
shorter survival when compared with patients demonstrating low MACC1 levels (P = 0.0015). Kaplan-Meier analyses for all gastric cancer patients based on MACC1; B: 
Overall survival of patients with primary gastric cancer with or without synchronous metastasis based on circulating transcript levels of metastasis associated in colon 
cancer 1. Newly diagnosed gastric cancer patients with high circulating MACC1 transcript levels in plasma demonstrated shorter survival when compared with patients 
demonstrating low MACC1 levels. Kaplan-Meier analyses for newly diagnosed gastric cancer patients based on MACC1; C: Overall survival of gastric cancer patients 
with both markers metastasis associated in colon cancer 1 and S100A4 highly expressed vs none or only one marker highly expressed. Gastric cancer patients with 
high circulating transcript levels of MACC1 as well as S100A4 in plasma demonstrated significantly shorter survival when compared with patients demonstrating low 
levels of both biomarkers or with only one biomarker elevated (P = 0.001). Kaplan-Meier analyses for all gastric cancer patients based on MACC1 and S100A4; D: 
Overall survival of gastric cancer patients with both markers metastasis associated in colon cancer 1 and S100A4 highly expressed, only one or none marker highly 
expressed. Patients were classified into groups of low expressers of both genes, of patients with high S100A4 levels, of patients with high MACC1 levels, or with high 
expression of both biomarkers. Gastric cancer patients with high circulating transcript levels of MACC1 as well as S100A4 in plasma demonstrated shorter survival 
when compared with patients demonstrating low levels of both biomarkers or with only one biomarker elevated. Kaplan-Meier analyses for all gastric cancer patients 
based on MACC1 and S100A4.
S100A4 high
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log rank rests. The cut-off  values of  high vs low MACC1 
transcripts levels were the median of  the investigated 
groups, respectively. First, we analyzed the MACC1 
levels of  all patients (primary diagnosis of  gastric cancer 
with and without synchronous metastasis, patients with 
metachronous metastasis and patients during follow up) 
with respect to overall survival. Patients with high MACC1 
transcript levels had a statistically significant worse overall 
survival compared with patients with low MACC1 levels 
(P = 0.015; Figure 2A) with a median follow-up period of  
803 d after blood taking. Additionally, also the subcohort 
of  patients with newly diagnosed gastric cancer and high 
MACC1 transcript levels demonstrated a shorter overall 
survival compared to patients with low MACC1 levels 
(Figure 2B) with a median follow-up period of  618 d after 
blood taking.
Combination of circulating MACC1 and S100A4 
transcript levels in plasma for improvement of gastric 
cancer patient survival prognosis
To improve the prognosis for patient survival, we added a 
further metastasis gene, S100A4, to this analysis. S100A4 
is known to contribute to metastasis formation for several 
cancers[13,14]. For gastric cancer, S100A4 is also linked 
to tumor progression and development of  metastasis 
as well as to disease prognosis when determined in the 
primary tumor tissue[15-20]. Previously we described the 
diagnostic and prognostic value of  S100A4 transcripts 
in plasma of  gastrointestinal cancer patients, such as for 
colon, rectal and gastric cancer patients[11]. Therefore, we 
combined here the analyses for circulating MACC1 as 
well as S100A4 transcripts to test for improvement of  the 
disease prognosis compared to analyses based exclusively 
on MACC1. First we compared two groups, those showing 
none or only one biomarker at high levels (n = 52), with 
patients demonstrating high levels of  both biomarkers (n = 
18). We demonstrated a significantly shorter overall survival 
for patients having both MACC1 as well as S100A4 at high 
levels (P = 0.01; Figure 2C). Remarkably, the combination 
of  the biomarkers improved the prognosis compared to 
the analyses based on each single biomarker. This is further 
illustrated, when classifying the patients into 4 groups, 
those showing both biomarkers at low levels (MACC1 
and S100A4 low), or with MACC1 high, or with S100A4 
high, or in a group of  patients showing high levels of  both 
biomarkers (MACC1 and S100A4 high) (Figure 2D).
Taken together, prognosis of  gastric cancer patient 
survival can be based on plasma levels of  circulating 
MACC1 transcripts, and can be improved when combining 
the information of  circulating transcripts of  both the 
metastasis biomarkers, MACC1 and S100A4.
DISCUSSION
Here we report the diagnostic and prognostic value of  
circulating MACC1 transcripts in blood of  patients with 
gastric cancer. Based on the levels of  circulating MACC1 
transcripts in plasma we significantly discriminate tumor-
free volunteers and gastric cancer patients. Furthermore 
we demonstrate in this prospective study that circulating 
MACC1 transcript levels in plasma are prognostic for the 
survival of  the gastric cancer patients. Finally we show, 
that the combination of  biomarkers, here MACC1 and 
S100A4, improve gastric cancer patient survival prognosis. 
Thus, the quantitative determination of  circulating 
transcript levels of  MACC1, as well as of  MACC1 and 
S100A4, is proven to be useful for gastric cancer patient 
survival prognosis.
We newly identified the gene MACC1 in colorectal 
cancer patients and demonstrated its prognostic value for 
colorectal cancer patient survival based on expression in 
patient tissue[3]. We showed its ability to induced cell motility 
in vitro and metastasis in mice. Moreover, we provided 
evidence for MACC1 as master regulator of  further 
metastasis genes, for instance of  the receptor tyrosine kinase 
Met[6]. Meanwhile, MACC1 is confirmed as biomarker 
by a large body of  publications for prognosis of  tumor 
progression and metastasis as well as for prediction of  
therapy response for a great variety of  solid cancers, linked 
to patient survival[4].
However, in order to overcome the limitation of  
prognosis generation based on the analysis of  only a very 
small number of  available tissues per patient, we developed 
this non-invasive blood-based assay for circulating 
transcripts[10,11]. This assay harbors the potential to be 
employed for screening of  the quantitation of  circulating 
MACC1 transcripts on a routine basis. It is clinically appli-
cable for diagnosis and prognosis of  cancer patients, as 
shown here for patients with gastric cancer. Furthermore, it 
might be also used for monitoring of  response to a defined 
treatment of  cancer patients. In addition, this assay can easily 
be translated for the quantitative determination of  further 
circulating transcripts which are of  diagnostic, prognostic 
and/or predictive value for a defined disease.
In this study, we significantly classified gastric cancer 
patients from tumor-free volunteers, based on this assay 
for circulating MACC1 transcripts. Interestingly, highest 
levels of  circulating MACC1 transcripts were found 
in individuals with metastases further underlining the 
diagnostic value of  circulating MACC1 transcripts in 
patient plasma with respect to metastasis formation. Most 
importantly, these prospectively determined high levels of  
MACC1 transcripts correlate with shorter survival of  the 
patients demonstrating the prognostic value of  circulating 
MACC1 transcripts. Thus, this assay could be used for 
patient screening as well as for metastasis detection during 
follow-up to identify the patient population at high risk. 
This finding might imply also importance for patient 
stratification in future studies.
Our findings of  circulating MACC1 transcripts in 
plasma of  gastric cancer patients for diagnosis and survival 
prognosis are in line with findings reported previously 
but based on the quantification of  MACC1 mRNA 
expression in gastric cancer tissues. Guo and colleagues 
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showed a correlation of  MACC1 in the primary gastric 
tumors with peritoneal metastasis, lymph node metastasis, 
hepatic metastasis, and finally to a poor prognosis for 
patients[7]. Wang and colleagues reported a correlation of  
high MACC1 expression in the primary tumors with more 
advanced disease, more frequent postoperative recurrence, 
more metastases, higher mortality rate, and shorter survival 
of  the gastric cancer patients[8]. Shirahata and colleagues 
demonstrated a correlation of  high expression of  MACC1 
in gastric tumors with peritoneal dissemination of  the 
tumor[9]. All of  these data point to the importance of  
MACC1 as a biomarker for tumor progression, metastasis 
and survival for gastric cancer patients. Moreover, these 
findings underline the relevance of  the further employment 
of  MACC1 as a biomarker to be quantitatively and 
repeatedly determined in gastric cancer patient blood.
Our new findings of  circulating MACC1 transcripts 
in plasma of  gastric cancer patients for diagnosis and 
prediction of  survival are also in line with those that we 
reported previously for colorectal cancer[10]. Thus, the 
use of  MACC1 as a biomarker from liquid biopsies for 
patient stratification might be extended from tissues to 
this blood-based assay allowing repeated measurements 
of  circulating MACC1 transcript levels.
Since the quantitative determination of  cell-free, 
circulating mRNA in blood as liquid biopsies allows 
real-time monitoring of  disease progress, prognosis, 
and therapeutic response[21], the combined detection 
of  different biomarkers in patient blood might offer 
additional options for improvement of  diagnosis, 
prognosis of  response prediction. Several markers, such 
as Carcino Embryonic Antigen, Carbohydrate Antigen 
19-9 and Carbohydrate Antigen 72-4 have determined in 
blood of  gastric cancer patients, however, with limited 
sensitivities (20%-30%)[22-24]. Recently the mRNA levels 
of  KRAB-ZFP-Associated Protein 1, Tissue Inhibitor of  
Metalloproteinases 1, and Stanniocalcin 2 were determined 
in peripheral blood samples from pre-operative gastric 
cancer patients, patients with recurrence, and healthy 
volunteers and were identified as potential biomarkers for 
screening, diagnosis, prognosis and surveillance of  gastric 
cancer[25]. Another recent report describes an association 
of  increased Bone Morphogenetic Protein 8b mRNA 
levels in peripheral blood of  gastric cancer patients with 
metastatic disease[26].
Here, we combined the data for circulating MACC1 
levels with those of  S100A4, a well-known metastasis-
inducing gene. S100A4 expression was linked to tumor 
progression and development of  metastasis and has been 
shown to be of  prognostic value when determined in 
the primary gastric tumors tissue[15-20]. Moreover, Kim 
and colleagues demonstrated that the combination of  
S100A4 and p53 are useful for prediction of  relapse in 
curatively resected stage Ⅲ and Ⅳ (M0) gastric cancer[17]. 
We already established this blood-based assay for S100A4 
and demonstrated the diagnostic and prognostic value of  
circulating S100A4 transcripts in colorectal cancer and in 
gastric cancer patients[11]. When we here combined the 
data of  two major metastasis-inducing genes, MACC1 
as master regulator of  the HGF/Met signaling axis[3,6] 
with those of  S100A4, a Wnt/β-catenin target gene[14], 
disease prognosis for gastric cancer patients was improved 
compared to those based exclusively on MACC1. We 
demonstrated significant differences of  overall survival for 
patients with high expression of  both markers compared 
to patients with a high expression of  none or only one 
marker. Thus, a combination of  biomarkers addressing 
different, but most relevant signaling pathways for tumor 
progression and metastasis might be most beneficial for 
improved prognosis of  patient survival. In addition, it has 
to be demonstrated, that a combination with further types 
of  free RNA in patient blood, such as miRNA, might 
result in even better disease prognosis and/or therapy 
response prediction.
In conclusion, survival of  gastric cancer patient can be 
predicted based on plasma levels of  circulating MACC1 
transcripts, and can be improved when combining the 
information of  circulating MACC1 transcripts with 
a further metastasis biomarker, S100A4. Both genes 
represent promising therapeutic targets and intervention 
strategies are desired aiming at restriction of  tumor 
progression and metastasis development. It has to be 
evaluated, if  this clinically applicable blood-based assay for 
circulating MACC1 transcripts in cancer patient plasma 
might represent an ideal read-out for predicting and for 
monitoring therapeutic response of  future interventions 
targeting MACC1 in gastric cancer patients.
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Background
Gastric cancer is one of the major malignancies in the world and still the fourth 
most common cause of death from cancer. Patient survival is clearly linked to 
disease stage and metastasis formation. Biomarkers for detecting the disease 
already in early stage and identifying patients at high risk for metastasis are 
crucial.
Research frontiers
The newly discovered gene Metastasis Associated in Colon Cancer 1 (MACC1) 
is highly acknowledged as prognostic and predictive biomarker for a variety of 
solid cancers. In gastric primary tumors, the presence of MACC1 correlated 
with peritoneal metastasis, lymph node metastasis and hepatic metastasis, 
and finally to a poor patient prognosis underlining the importance of MACC1 as 
biomarker for tumor progression, metastasis and survival also for gastric cancer 
patients.
Innovations and breakthroughs
The authors provide for the first time a blood-based assay for transcript 
quantification of the metastasis inducer MACC1 in a prospective study of gastric 
cancer patient plasma. Based on the levels of circulating MACC1 transcripts 
in plasma we discriminated tumor-free volunteers and gastric cancer patients. 
Levels of circulating MACC1 transcripts were increased in gastric cancer 
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patients of each disease stage, compared to tumor-free volunteers. Importantly, 
gastric cancer patients with high circulating MACC1 transcript levels in plasma 
demonstrated significantly shorter survival when compared with patients 
demonstrating low MACC1 levels. Furthermore, gastric cancer patients with 
high circulating transcript levels of MACC1 as well as of S100A4 in plasma 
demonstrated shorter survival when compared with patients demonstrating low 
levels of both biomarkers or with only one biomarker elevated.
Applications
This prospective study suggests that quantitative determination of circulating 
transcript levels of MACC1, as well as of MACC1 and S100A4, in plasma of 
gastric cancer patients is proven to be useful for survival prognosis.
Terminology
In previous studies we have identified the novel gene MACC1, Metastasis-
Associated in Colon Cancer. MACC1 is a strong prognostic and predictive 
biomarker for tumor progression and metastasis in a variety of solid cancers. 
MACC1 is confirmed as decisive driver for tumorigenesis and metastasis. 
S100A4, S100 Calcium Binding Protein A4, is also linked to tumor progression 
and metastasis formation and has been shown to be of prognostic value for 
primary gastric and further tumors.
Peer review
The m/s presents an interesting research study concerning the quantitation of 
MACC1 transcript in blood of gastric cancer patients. Quantitative results were 
compared in terms of cancer metastases and overall survival of patients and 
also in conjugation with another proposed biomarker, S100A4. The research 
article “circulating MACC1 transcripts in gastric cancer patient plasma as 
diagnostic and prognostic biomarker” by Burock et al 2015 provides a useful 
insight into the use of MACC1 transcripts to provide a biomarker for gastric 
cancer, and associated patient survival rates. The manuscript is interesting 
and draws upon sound clinical data sets. Overall it is a well-written manuscript 
which addresses an important research question.
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